GHK-Cu is a naturally occurring copper-tripeptide complex that declines with age and is used topically and by injection to support skin repair, wound healing, and hair growth.
What it does
GHK-Cu (Glycyl-L-Histidyl-L-Lysine bound to a copper ion) is found in human plasma, saliva, and urine. Plasma concentrations drop from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60 — a decline that tracks closely with visible signs of skin aging. The peptide works through several distinct pathways rather than one single mechanism. Its most studied action is stimulating fibroblasts (the cells that build connective tissue) to produce collagen I and III via the TGF-β signaling pathway, while also promoting decorin, a protein that organizes collagen fibers into orderly structures Die 2025 Valentina 2025. Separately, it activates matrix metalloproteinases (MMPs) — enzymes that break down damaged extracellular matrix (ECM, the structural scaffold of skin) — while simultaneously driving synthesis of replacement collagen, elastin, and glycosaminoglycans (hydrating sugar-protein molecules). This controlled remodeling distinguishes GHK-Cu from simpler collagen boosters Yiding 2024. The copper it delivers also activates superoxide dismutase (SOD), a key antioxidant enzyme that neutralizes reactive oxygen species, reduces lipid peroxidation, and limits iron-catalyzed oxidative damage Jin-Hong 2024 Yan 2024. On the inflammatory side, GHK-Cu suppresses NF-κB signaling, which lowers TNF-α and IL-6 — pro-inflammatory cytokines — and reduces excessive scar-forming activity driven by TGF-β Yiding 2024 Die 2025. Genome-wide studies show the peptide shifts expression of over 4,000 genes, with roughly 59% of those changes moving toward patterns seen in younger tissue, including upregulation of DNA repair genes Han 2025. For hair, it appears to enlarge follicles (shifting vellus, or fine, hairs toward terminal, or full, hairs), extend the active growth phase (anagen), and increase follicle blood supply via VEGF (vascular endothelial growth factor). There is also early evidence of NGF-like nerve growth signaling that promotes Schwann cell migration and nerve fiber regeneration, though this is largely preclinical Valentina 2025.
What the evidence shows
Skin rejuvenation and collagen synthesis Strong in vitro and rodent evidence; limited controlled human data
In cell and animal models, GHK-Cu reliably increases collagen I and III output, organizes ECM, and reduces oxidative damage in skin Die 2025 Yan 2024. Liposomal and microemulsion delivery systems have been developed specifically to improve topical penetration, though skin permeation of encapsulated GHK-Cu remains an active measurement challenge Karolina 2025 Joanna 2024 Tianqi 2024. A registered human trial (NCT05932732) is examining facial skin hydration and barrier function following topical GHK-Cu treatments, but results are not yet published. Human evidence currently rests largely on industry-funded cosmetic studies and self-reports rather than independent randomized controlled trials.
Wound healing Moderate in vitro and animal evidence; one registered human trial ongoing
GHK-Cu promotes angiogenesis (new blood vessel formation), ECM remodeling, and anti-inflammatory signaling — all relevant to wound repair Han 2025 Valentina 2025. A copper-tripeptide self-healing hydrogel showed accelerated infected wound closure in preclinical models Han 2025. A registered human trial (NCT07437586) is specifically evaluating topical GHK-Cu gel for acute skin wound healing, but no results are available yet. The mechanistic case is coherent; controlled human evidence is pending.
Lung inflammation and fibrosis Early animal evidence, no human trials
In a silicosis (lung scarring from silica dust) mouse model, GHK-Cu reduced lung inflammation and fibrosis by targeting peroxiredoxin 6, an antioxidant enzyme involved in oxidative injury Yiding 2024. This is a notable finding given the peptide's known anti-inflammatory pathway, but there are no human trials in pulmonary disease.
Neuroprotection In vitro only
GHK-Cu prevented copper- and zinc-induced protein aggregation and cell death in central nervous system cell cultures Jin-Hong 2024. Protein aggregation is a feature of several neurodegenerative diseases, making this a hypothesis-generating finding — but nothing beyond cell studies exists yet.
Hair growth Mostly anecdotal in humans; plausible mechanistic basis
GHK-Cu is reported to enlarge hair follicles and extend the anagen phase via VEGF-driven blood supply increases. These mechanisms are documented in vitro, and topical GHK-Cu formulations appear in several hair-loss products. Controlled human trial data on this specific use case is absent from the published literature.
How it's used
In studies and self-reported protocols, topical concentrations range from 0.05% applied once daily (lower end) to 0.1% applied once or twice daily; evening application is common to align with overnight skin repair cycles Karolina 2025 Tianqi 2024. Microneedling with GHK-Cu serums is also reported, intended to enhance dermal penetration. For systemic use, injectable (subcutaneous) doses in self-reported protocols range from 1–2 mg once weekly at the low end to 2–3 mg two to three times weekly at higher ranges, typically in short courses. The systemic half-life is approximately one hour, so frequent dosing is used to maintain exposure. Absolute contraindications include Wilson's disease (a genetic condition causing copper accumulation) and known copper hypersensitivity. Use in pregnancy lacks safety data.
Side effects and safety
Reported side effects are mild and infrequent. Topical use occasionally causes local skin irritation or redness. Injectable use has produced injection-site redness in some self-reports. Mild nausea and headache have been noted at higher doses, though these are not consistently documented in formal studies. No severe adverse events are documented in the available literature Die 2025 Han 2025. Long-term safety data — particularly for repeated systemic use — does not exist. Because GHK-Cu delivers bioavailable copper, anyone with impaired copper metabolism should avoid it entirely. The peptide's broad gene-expression effects (4,000+ genes) are described as restorative, but the long-term consequences of sustained systemic modulation of that scale are unknown.
Bottom line
GHK-Cu has a well-characterized mechanism and strong preclinical support for skin repair, ECM remodeling, and anti-inflammatory effects, but controlled human trial data remains thin — two registered trials are ongoing and unpublished. It is a reasonable topical agent for skin health given its safety profile; systemic use involves more uncertainty and should be approached with that in mind.